Venus Remedies
NSE: VENUSREM · ISIN INE411B01019 · Healthcare
₹1,448.80−62.10 (−4.11%)
Monday 9 November, 12:57 IST. Delayed. Source: Yahoo Finance.
Price chart
₹1,448.80 −62.10 (−4.11%) today
The day
- Previous close
- ₹1,510.90
- Open
- ₹1,510.90
- Day high
- ₹1,525.00
- Day low
- ₹1,435.40
Listed on NSE since 20 December 2006.
Key numbers
- Market value
- ₹2,021.99 Cr
- P/E (trailing)
- 16.60
- EPS (trailing)
- ₹91.04
- Price to book
- 2.87
- Dividend yield
- 0.66%
- Return on equity
- 18.7%
- Debt to equity
- 0.02
- Profit margin
- 14.5%
- Beta
- 0.45
- Volume today
- 16,230
- Average volume
- 37,613
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹553.38 Cr | ₹26.57 Cr |
| FY24 | ₹591.45 Cr | ₹28.49 Cr |
| FY25 | ₹647.29 Cr | ₹45.31 Cr |
| FY26 | ₹734.54 Cr | ₹102.79 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹219 Cr | ₹0 | – |
| Q1 FY27Apr–Jun 2026 | ₹179 Cr | ₹0 | – |
| Q4 FY26Jan–Mar 2026Audited | ₹259 Cr | ₹0 | −100.0% |
| Q3 FY26Oct–Dec 2025 | ₹180 Cr | ₹0 | – |
| Q2 FY26Jul–Sep 2025 | ₹193 Cr | ₹0 | – |
| Q1 FY26Apr–Jun 2025 | ₹132 Cr | ₹0 | – |
Source: Venus Remedies’s results filed with NSE, consolidated (the whole group). Net profit is the share of Venus Remedies’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹195 Cr | ₹177 Cr |
| Investments | ₹240 Cr | ₹238 Cr |
| Inventories | ₹132 Cr | ₹129 Cr |
| Owed by customers | ₹88 Cr | ₹103 Cr |
| Cash and equivalents | ₹18 Cr | ₹25 Cr |
| Total assets | ₹840 Cr | ₹854 Cr |
| Borrowings | ₹0 | ₹0 |
| Total liabilities | ₹135 Cr | ₹190 Cr |
| Shareholders’ equity | ₹705 Cr | ₹664 Cr |
Source: Venus Remedies’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Venus Remedies
Venus Remedies Limited engages in the pharmaceutical business in India, Latin America, Europe, the Middle East, Africa, Asia, and internationally. The company is involved in the research and development of solutions focusing on antimicrobial resistance, oncology, skin and wound care, and pain management. It also provides analgesic, analgesic and antipyretic, antibiotic, antidiabetic anticoagulant, antiemetic, antiviral, cardiac, cardiovascular, CNS, disinfectant and antiseptic, gastro therapy, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, mucolytic, muscle relaxant, neurology, respiratory, stress reliver, urology, vitamins, nutrients, minerals, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Panchkula
- Employees
- 1,472
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Venus Remedies in the last day or two.
Dividends and corporate actions
All companies- Dividend - Rs 10 Per Share
Dividend · ex-date 7 August 2026
- Annual General Meeting
Action · ex-date 13 September 2024
- Annual General Meeting
Action · ex-date 17 August 2023
- Annual General Meeting
Action · ex-date 11 August 2022
- Annual General Meeting
Action · ex-date 9 September 2021
- Annual General Meeting
Action · ex-date 24 November 2020
- Annual General Meeting
Action · ex-date 20 September 2019
- Annual General Meeting
Action · ex-date 14 September 2018
Source: NSE. Latest first, 8 of 19.
Information only, not investment advice. Prices are delayed.